Medtronic (MDT) Stock Down 26%: Why Wall Street Sees 50% Upside Ahead

Key Takeaways

Table of Contents

Fourth-quarter revenue reached $9.7 billion, climbing 9.9% versus last year—marking the company’s most robust annual revenue expansion in ten years
Shares currently trade at 13.5x projected earnings, below the historical 10-year median of 16x and beneath valuations of competitors including Abbott and Stryker
Cardiac Ablation Solutions delivered 78% global revenue growth and 124% expansion in U.S. markets, capturing significant share from Boston Scientific
Hugo robotic surgical platform carries pricing approximately 40% lower than Intuitive Surgical’s da Vinci, addressing a market forecast to surpass $54 billion
Wall Street firms TD Cowen and RBC Capital Markets maintain price objectives of $119 and $118, suggesting potential gains exceeding 50% from present levels

Medtronic (MDT) stock has endured a challenging period in recent years. The medical device powerhouse developed a track record of underdelivering on expectations, and share prices have suffered accordingly. However, recent developments suggest a meaningful shift is underway.

Medtronic plc, MDT

The organization’s fiscal 2026 fourth-quarter earnings, disclosed on June 3, exceeded analyst projections. Sales climbed 9.9% compared to the prior year, reaching $9.7 billion. This propelled full-year expansion to 8.4%—representing the company’s strongest annual revenue performance in a full decade.

MDT shares currently hover near $78, having retreated from a 52-week peak of $106.33. With a forward earnings multiple of 13.5 and a dividend yield of 3.7%, the valuation appears attractive both versus historical norms and competitive benchmarks.

The company’s decade-long average forward price-to-earnings ratio approaches 16. Industry peers such as Abbott, Boston Scientific, Johnson & Johnson, and Stryker command price-to-sales ratios near 4. Medtronic’s metric stands at just 2.8.

RBC Capital Markets analyst Shagun Singh maintains an Outperform rating alongside a $118 price objective. TD Cowen reaffirmed its Buy recommendation with a $119 target. Both firms emphasize the same catalyst: Medtronic is entering the early stages of a significant product innovation cycle.

Cardiac Ablation Business Drives Momentum

The cardiovascular division represents the brightest spot in the portfolio. Accounting for approximately 39% of consolidated revenue, this segment expanded 10% year-over-year to $3.8 billion during the most recent quarter.

Within this division, Cardiac Ablation Solutions (CAS) demonstrates exceptional momentum. Revenue soared 78% on a global basis and 124% within U.S. markets. The franchise is expanding at double the underlying market growth rate while capturing eight percentage points of market share.

This share gain comes directly at Boston Scientific’s expense, which acknowledged lost PFA market position as a factor behind its reduced full-year guidance. Boston Scientific shares have tumbled 51% year-to-date.

Medtronic’s competitive advantage stems from being the sole provider with dual FDA-approved pulsed field ablation platforms: PulseSelect and the Affera System. Affera integrates PFA and radiofrequency energy with comprehensive cardiac mapping capabilities. CEO Geoff Martha noted that the U.S. installed base expanded 40% sequentially in the latest quarter.

Hugo Robotic System and Surgical Innovation

Beyond cardiovascular applications, Medtronic’s Hugo robotic-assisted surgical platform represents one of the portfolio’s most compelling long-term opportunities.

Hugo secured FDA authorization for urological procedures in 2025. The organization has submitted applications for general surgery and gynecological indications. The system carries pricing approximately 40% beneath Intuitive Surgical’s da Vinci platform.

Robotic-assisted procedures currently represent under 5% of total surgical volume globally. Industry projections estimate the worldwide market will expand beyond $54 billion throughout the coming decade.

In the neuroscience division, fourth-quarter revenue advanced 5%. Medtronic also obtained FDA clearance this year for an innovative Stealth AXiS Spine application designed for brain surgery, broadening its AiBLE surgical ecosystem.

Regarding renal treatments, Needham reaffirmed its Buy rating and $101 price target this week, highlighting Symplicity Spyral sales trending toward a $100 million annual run rate. Medicare reimbursement commenced in October 2025.

For fiscal 2027, Medtronic projects organic revenue growth between 6.75% and 7.25%, with adjusted earnings per share ranging from $5.90 to $6.00—representing approximately 8% growth from the prior year’s $5.53.

The corporation has increased its dividend distribution for 49 consecutive years. The present quarterly dividend stands at $0.72 per share.

✨ Limited Time Offer